An interventional study of Voice assistant in Heart Failure, Diabetes Mellitus and Arterial Hypertension, sponsored by I.M. Sechenov First Moscow State Medical University. Not yet recruiting at 1 site in Russian Federation. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-16.
Sponsored by I.M. Sechenov First Moscow State Medical University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Heart Failure by I.M. Sechenov First Moscow State Medical University — 4 open to participants now, 4 under way, none of them phase 3. Heart Failure · I.M. Sechenov First Moscow State Medical University.
Among the 10 studies in Heart Failure by I.M. Sechenov First Moscow State Medical University, this one is the only one that started in 2024, is one of 2 with no phase, and was the 7th registered.
6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.
Browse Heart Failure studies →4 of the 10 studies in Heart Failure by I.M. Sechenov First Moscow State Medical University are open now, in 2 countries. Recruiting first, the newest first:
I.M. Sechenov First Moscow State Medical University · Sites in Russia
Ages 18+
I.M. Sechenov First Moscow State Medical University
Ages 18+ · Healthy volunteers
I.M. Sechenov First Moscow State Medical University · Sites in Russian Federation
Ages 40+
By country, each count listing its studies:
Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2019; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 500 is above the median of 76 across 4,053 interventional studies indexed under Heart Failure.
Median enrollment 66 across the 5 interventional studies, 400 across the 5 observational. Of the 6 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
I.M. Sechenov First Moscow State Medical University is the lead sponsor of 137 studies on the registry; 28 are open to participants now.
1 of the studies in Heart Failure by I.M. Sechenov First Moscow State Medical University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07552142I.M. Sechenov First Moscow State Medical UniversityPatient-Reported Health Status Assessment Using the KCCQ for Early Detection of Heart Failure Worsening | 2027-10-01 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies in Heart Failure by I.M. Sechenov First Moscow State Medical University, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
DIALOG is a study to assess the efficacy and safety of remote patient monitoring using virtual operator voice technologies and a business intelligence (BI) system for timely detection, prevention of early complications, worsening of the condition, and other adverse events in patients who have been discharged from the hospital.
After ensuring that the patient\'s characteristics meet the inclusion and exclusion criteria and confirming the patient\'s ability to use the \"voice assistant\", as provided in the research protocol, patients who have completed the briefing will be able to use the voice assistant at home. During the month, robotic remote monitoring of patients using unique algorithms developed for virtual operator speech technology and a BI system will be conducted for five groups of patients (CHF, DM, AH, LPD, and patients who underwent total knee replacement) who have been discharged from the hospital. The system developed allows for quick surveys, collection of data on patient conditions, and convenient transfer of this data to the physician. The physician will receive information on patient status in a graphical form using a traffic light system. In the event of any red flags, the physician will contact the patient for further discussion on treatment strategies. The study will evaluate the efficacy and safety of utilizing the \"voice assistant\" by assessing the achievement of target values for controlled parameters, evaluating patient satisfaction and adherence to treatment, reducing the number of repeat hospitalization, and reducing overall mortality and cardiovascular-related mortality.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Non-inclusion criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with chronic heart failure who was hospitalized due to decompensation of their condition. Their condition should be stabilized before discharge. Robotic remote monitoring of patients using unique algorithms developed for virtual operator speech technology and a BI system by voice commands to automate data collection and obtain information about the patient's well-being and his vital signs (blood pressure, heart rate, weight) related to heart failure.
Device: Voice assistant
Patients with diabetes mellitus who was hospitalized with unstable glucose level. Their condition should be stabilized before discharge. Robotic remote monitoring of patients using unique algorithms developed for virtual operator speech technology and a BI system by voice commands to automate data collection and obtain information about the patient's well-being and his vital signs (blood pressure, heart rate, weight, glucose) related to diabetes mellitus.
Device: Voice assistant
Patients with arterial hypertension who was hospitalized with unstable arterial pressure. Their condition should be stabilized before discharge. Robotic remote monitoring of patients using unique algorithms developed for virtual operator speech technology and a BI system by voice commands to automate data collection and obtain information about the patient's well-being and his vital signs (blood pressure, heart rate, hypotension sings, signs of damage to target organs).
Device: Voice assistant
Patients with any lymphoproliferative disease who is undergoing chemotherapy. Their condition should be stabilized before discharge. Robotic remote monitoring of patients using unique algorithms developed for virtual operator speech technology and a BI system by voice commands to automate data collection and obtain information about the patient's well-being and his vital signs (blood pressure, heart rate) related to chemotherapy complications.
Device: Voice assistant
Patients who underwent total knee replacement. Their condition should be stabilized before discharge. Robotic remote monitoring of patients using unique algorithms developed for virtual operator speech technology and a BI system by voice commands to automate data collection and obtain information about the patient's well-being and his vital signs (pain, fever) related to replacement complications.
Device: Voice assistant
Robotic remote monitoring of patients using unique algorithms developed for virtual operator speech technology and a BI system by voice commands on the "question-answer" principle. It allows us to automate data collection and obtain information about the patient's well-being and his vital signs (blood pressure, heart rate, weight) depending on disease. Follow-up and management of disease provided by specialists at participating institutions.
cardiovascular mortality
mortality rate
Time frame: an average, 1 month after randomization
all-cause mortality
mortality rate
Time frame: an average, 1 months after randomization
complications, decompensations
rate of complications and exacerbations of the main disease
Time frame: an average, 1 month after randomization
achievement target or maximally tolerated doses
achievement target or maximally tolerated doses for CHF, DM and AH
Time frame: an average, 1 month after randomization
satisfaction
satisfaction of patients and doctors with the robotic speech questionnaire
Time frame: an average, 1 month after randomization
changes in medical adherence
change in amount of taking drugs and doses
Time frame: an average, 1 month after randomization
Plan to share: No — According to the Local Ethics Committee\'s rules, we are not allowed to provide this data.
No publications or documents are linked to this record.
Start is estimated for Oct 2024; primary completion for Feb 2025, 4 months later.
Of 1,119 non-industry interventional studies with no phase under Heart Failure, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 50. This study's planned 4 months is below that.
Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
I.M. Sechenov First Moscow State Medical University →